Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | CPA1 | P15085 | 2/20 | 0.59 |
| ▸ | FPR2 | P25090 | 5/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547222 | 1.00 | MME (0.67) | MMEL3MBTL1NPSR1NAALAD2ACE2 | |
| SCHEMBL1696507 | 1.00 | MME (0.67) | MMEL3MBTL1NPSR1NAALAD2ACE2 | |
| SCHEMBL18180178 | 0.88 | NAALAD2 (0.78) | MMEL3MBTL1NPSR1NAALAD2FPR2 | |
| SCHEMBL19969196 | 0.88 | NAALAD2 (0.78) | MMEL3MBTL1NPSR1NAALAD2FPR2 | |
| SCHEMBL10795720 | 0.87 | MME (0.62) | MMEL3MBTL1NPSR1NAALAD2ACE2 | |
| SCHEMBL5841327 | 0.86 | MME (0.65) | MMEL3MBTL1NPSR1NAALAD2ACE2 | |
| SCHEMBL1012053 | 0.85 | MME (0.63) | MMEL3MBTL1NPSR1NAALAD2ACE2 | |
| Afalanine SCHEMBL331330 | 0.85 | CTSS (0.65) | MMEL3MBTL1NPSR1NAALAD2ACE2 | |
| SCHEMBL4028404 | 0.85 | ALDH1A1 (0.57) | MMEL3MBTL1 | |
| SCHEMBL17785192 | 0.85 | MME (0.68) | MMEL3MBTL1NPSR1NAALAD2ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116162255-B | Charge-convertible dendrimer and preparation method thereof | 东莞理工学院 | 2024-07-09 | — | — | CN | claimed |
| EP-4274838-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| EP-4199968-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | Ambrx, Inc. (US) | 2023-06-28 | — | — | EP | claimed |
| EP-4117732-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Ambrx, Inc. (US) | 2023-01-18 | — | — | EP | claimed |
| WO-2022148974-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | claimed |
| WO-2022040596-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2022-02-24 | — | — | WO | claimed |
| EP-3923991-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | Ambrx, Inc. (US) | 2021-12-22 | — | — | EP | claimed |
| WO-2021183832-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. (US) | 2021-09-16 | — | — | WO | claimed |
| EP-3844188-A1 | ANTI-CD3 ANTIBODY FOLATE BIOCONJUGATES AND THEIR USES | Ambrx, Inc. (US) | 2021-07-07 | — | — | EP | claimed |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2021-05-13 | — | — | US | claimed |
| EP-2249865-A2 | BREAKING IMMUNOLOGICAL TOLERANCE WITH A GENETICALLY ENCODED UNNATURAL AMINO ACID | The Scripps Research Institute (US) | 2010-11-17 | — | — | EP | claimed |
| WO-2009099672-A2 | BREAKING IMMUNOLOGICAL TOLERANCE WITH A GENETICALLY ENCODED UNNATURAL AMINO ACID | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | claimed |
| EP-2081602-A2 | TOXIN PEPTIDE THERAPEUTIC AGENTS | Amgen Inc. (US) | 2009-07-29 | — | — | EP | claimed |
| WO-2008088422-A2 | TOXIN PEPTIDE THERAPEUTIC AGENTS | AMGEN INC. (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1793843-A1 | MACROCYCLIC SH2 DOMAIN BINDING INHIBITORS | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006039527-A1 | MACROCYCLIC SH2 DOMAIN BINDING INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-13 | — | — | WO | claimed |
| WO-2006017619-A2 | RECEPTOR-BINDING CYCLIC PEPTIDES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060029544-A1 | Receptor-binding cyclic peptides and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2006-02-09 | — | — | US | claimed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | claimed |
| EP-0009777-B1 | RETINOIC- AND 7,8-DEHYDRO-RETINOIC-ACID-N-(CARBOXY)PHENYL AMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1982-05-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | MME 2617/4885L3MBTL1 4015/4885NPSR1 2141/4885 |
| US-20060029544-A1 | Receptor-binding cyclic peptides and methods of use | ITGB3, ITGB5, ITGA5 | MME 3723/4885L3MBTL1 2786/4885NPSR1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.